.Pharmacolibrary.Drugs.C_CardiovascularSystem.C07A_BetaBlockingAgents.C07AG01_Labetalol.Labetalol

Information

Labetalol is a combined alpha- and beta-adrenergic receptor antagonist used primarily for the treatment of hypertension, including hypertensive emergencies and chronic hypertension. It is approved for clinical use and is widely prescribed today.

Pharmacokinetics

Pharmacokinetic parameters derived from healthy adult volunteers after a single intravenous dose.

References

1. Chera-Aree, P, et al., & Wataganara, T (2020). Clinical Experiences of Intravenous Hydralazine and Labetalol for Acute Treatment of Severe Hypertension in Pregnant Thai Women. Journal of clinical pharmacology 60(12) 1662–1670. DOI:10.1002/jcph.1685 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32598488

2. Hafsa, H, et al., & Alqahtani, F (2022). Development and Evaluation of a Physiologically Based Pharmacokinetic Model of Labetalol in Healthy and Diseased Populations. Pharmaceutics 14(11) –. DOI:10.3390/pharmaceutics14112362 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36365181

3. Rasmussen, BB, et al., & Senderovitz, T (2005). Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers. BJOG : an international journal of obstetrics and gynaecology 112(11) 1492–1499. DOI:10.1111/j.1471-0528.2005.00735.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/16225568

Revisions

• 06/2025 initial generated model